Biogen | Sustainability Performance
Operates in the biotechnology sector, concentrating on the development of therapies for neurological and neurodegenerative diseases. The company engages in research and development, emphasizing innovation to address unmet medical needs in patient populations.
1978
United States
5,001 - 10,000 employees
Biotechnology
$1B - 10B in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#646
Overallⓘ#162
in United Statesⓘ#11
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsCarbon certificatesDigital emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Laggard
Aligned
Aligned
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
9.1
B/M 10.8
36.0
B/M 128.6
44.9
B/M 27.9
Powered by illuminem and GIST Impact
Controversy level
- Biogen paid USD 900 million to settle whistleblower claims of paying kickbacks to physicians prescribing MS drugs.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.